Yi-Ji Liao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2801506/publications.pdf

Version: 2024-02-01

47 papers	2,905 citations	218677 26 h-index	214800 47 g-index
53 all docs	53 docs citations	53 times ranked	5508 citing authors

#	Article	IF	Citations
1	Epigenetic regulation of prostate cancer: the theories and the clinical implications. Asian Journal of Andrology, 2019, 21, 279.	1.6	32
2	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2â€“ERÎ±â€“GREB1 Transcriptional Axis. Cancer Research, 2018, 78, 671-684.	0.9	80
3	Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis. Stem Cells, 2018, 36, 180-191.	3.2	24
4	FMNL1 mediates nasopharyngeal carcinoma cell aggressiveness by epigenetically upregulating MTA1. Oncogene, 2018, 37, 6243-6258.	5.9	24
5	Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1. Oncotarget, 2016, 7, 26535-26550.	1.8	77
6	CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma. Carcinogenesis, 2016, 37, 557-566.	2.8	30
7	The putative tumor activator ARHGEF3 promotes nasopharyngeal carcinoma cell pathogenesis by inhibiting cellular apoptosis. Oncotarget, 2016, 7, 25836-25848.	1.8	15
8	Evidence for transcriptional interference in a dual-luciferase reporter system. Scientific Reports, 2015, 5, 17675.	3.3	11
9	MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets. BMC Cancer, 2015, 15, 706.	2.6	59
10	Low expression of <scp>BARX2</scp> in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatology Research, 2015, 45, 228-237.	3.4	24
11	Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma. Tumor Biology, 2015, 36, 4405-4415.	1.8	7
12	Systemic Delivery of MicroRNA-101 Potently Inhibits Hepatocellular Carcinoma In Vivo by Repressing Multiple Targets. PLoS Genetics, 2015, 11, e1004873.	3.5	90
13	MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clinical Cancer Research, 2015, 21, 4881-4891.	7.0	51
14	ULK1: A Promising Biomarker in Predicting Poor Prognosis and Therapeutic Response in Human Nasopharygeal Carcinoma. PLoS ONE, 2015, 10, e0117375.	2.5	35
15	Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer. World Journal of Gastroenterology, 2015, 21, 9916.	3.3	23
16	Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression. Oncotarget, 2014, 5, 6716-6733.	1.8	22
17	Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma. BMC Cancer, 2014, 14, 583.	2.6	29
18	Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death and Disease, 2014, 5, e1137-e1137.	6.3	75

#	Article	IF	Citations
19	Î±4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. European Journal of Cancer, 2014, 50, 840-851.	2.8	11
20	OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. Molecular Cancer, 2014, 13, 191.	19.2	71
21	The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas. Cancer Letters, 2014, 353, 104-114.	7.2	22
22	Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncology, The, 2013, 14, 1295-1306.	10.7	514
23	Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer, 2013, 13, 349.	2.6	98
24	PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. Molecular Cancer, 2013, 12, 148.	19.2	28
25	The telomere/telomerase binding factor <scp>PinX1</scp> is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas. Journal of Pathology, 2013, 229, 765-774.	4.5	25
26	MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Letters, 2013, 329, 91-98.	7.2	76
27	High Expression of H3K27me3 Is an Independent Predictor of Worse Outcome in Patients with Urothelial Carcinoma of Bladder Treated with Radical Cystectomy. BioMed Research International, 2013, 2013, 1-8.	1.9	17
28	Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelialâ€“mesenchymaltransition. Gut, 2012, 61, 562-575.	12.1	153
29	The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumor Biology, 2012, 33, 1115-1123.	1.8	12
30	CHD1L Protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer, 2012, 12, 437.	2.6	41
31	Overexpression of the secretory small GTPase Rab27B in human breast cancer correlates closely with lymph node metastasis and predicts poor prognosis. Journal of Translational Medicine, 2012, 10, 242.	4.4	39
32	Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3. Journal of Translational Medicine, 2012, 10, 249.	4.4	33
33	Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma. Medical Oncology, 2012, 29, 2669-2676.	2.5	18
34	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut, 2012, 61, 278-289.	12.1	373
35	The nucleotide polymorphisms within the Epsteinâ€“Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro. European Archives of Oto-Rhino-Laryngology, 2012, 269, 931-938.	1.6	9
36	Heat shock factor 1 upregulates transcription of Epsteinâ€“Barr Virus nuclear antigen 1 by binding to a heat shock element within the BamHI-Q promoter. Virology, 2011, 421, 184-191.	2.4	15

#	Article	IF	Citations
37	EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut, 2011, 60, 967-976.	12.1	162
38	The enhanced transcriptional activity of the V-val subtype of Epstein-Barr virus nuclear antigen 1 in epithelial cell lines. Oncology Reports, 2010, 23, 1417-24.	2.6	8
39	PYRIN domain of NALP2 inhibits cell proliferation and tumor growth of human glioblastoma. Plasmid, 2010, 64, 41-50.	1.4	9
40	Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. European Journal of Pharmacology, 2010, 637, 16-21.	3.5	98
41	High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. International Journal of Cancer, 2010, 127, 138-147.	5.1	76
42	Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1123-1128.	2.8	23
43	EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-Î²1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis, 2010, 31, 1576-1583.	2.8	136
44	Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer, 2009, 9, 461.	2.6	55
45	Cell cycleâ€related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. International Journal of Cancer, 2009, 125, 2631-2642.	5.1	27
46	Overexpression of EIFâ€5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. Cancer Science, 2009, 100, 896-902.	3.9	26
47	Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Science, 2009, 100, 2354-2360.	3.9	22